PURPOSE: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). PATIENTS AND METHODS: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. RESULTS: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 10(9)/L were noted in 65%, and platelets counts <30 × 10(9)/L in 26%. Each platelets count drop below the range of 200 × 10(9)/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 10(9)/L were studied. Platelet cutoffs of 30, 50, and 200 × 10(9)/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. CONCLUSION: Prognosis in MDS is directly associated with the severity of thrombocytopenia. 2011 Elsevier Inc. All rights reserved.
PURPOSE: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). PATIENTS AND METHODS: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. RESULTS: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 10(9)/L were noted in 65%, and platelets counts <30 × 10(9)/L in 26%. Each platelets count drop below the range of 200 × 10(9)/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 10(9)/L were studied. Platelet cutoffs of 30, 50, and 200 × 10(9)/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. CONCLUSION: Prognosis in MDS is directly associated with the severity of thrombocytopenia. 2011 Elsevier Inc. All rights reserved.
Authors: B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Farshid Dayyani; Anthony P Conley; Sara S Strom; William Stevenson; Jorge E Cortes; Gautam Borthakur; Stefan Faderl; Susan O'Brien; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero Journal: Cancer Date: 2010-05-01 Impact factor: 6.860
Authors: Hagop Kantarjian; Pierre Fenaux; Mikkael A Sekeres; Pamela S Becker; Adam Boruchov; David Bowen; Eva Hellstrom-Lindberg; Richard A Larson; Roger M Lyons; Petra Muus; Jamile Shammo; Robert Siegel; Kuolung Hu; Janet Franklin; Dietmar P Berger Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero Journal: Cancer Date: 2008-09-15 Impact factor: 6.860
Authors: Hagop Kantarjian; Francis Giles; Alan List; Roger Lyons; Mikkael A Sekeres; Sherry Pierce; Robert Deuson; Joseph Leveque Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao Journal: Haematologica Date: 2012-01-22 Impact factor: 9.941
Authors: Guillermo Garcia-Manero; Valeria Santini; Antonio Almeida; Uwe Platzbecker; Anna Jonasova; Lewis R Silverman; Jose Falantes; Gianluigi Reda; Francesco Buccisano; Pierre Fenaux; Rena Buckstein; Maria Diez Campelo; Stephen Larsen; David Valcarcel; Paresh Vyas; Valentina Giai; Esther Natalie Olíva; Jake Shortt; Dietger Niederwieser; Moshe Mittelman; Luana Fianchi; Ignazia La Torre; Jianhua Zhong; Eric Laille; Daniel Lopes de Menezes; Barry Skikne; C L Beach; Aristoteles Giagounidis Journal: J Clin Oncol Date: 2021-03-25 Impact factor: 44.544